Bausch Health Companies Inc

Chart & Performance

D1W1MN

P/E

—

P/S

0.31

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

0.84%

Rev. gr., 5y

0.88%

Revenues

8.76b

+7.79%

Net income

-592m

L+179.25%

CFO

1.03b

Dividend

Nov 10, 20101 USD/sh

Earnings

Feb 20, 2025

Profile

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

URL

https://www.bauschhealth.com/

IPO date

Sep 20, 1994

Employees

19,900

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	8,757,000 7.79%	8,124,000 -3.68%	8,434,000 5.07%
Cost of revenue	6,058,000	5,518,000	5,483,000
Unusual Expense (Income)
NOPBT	2,699,000	2,606,000	2,951,000
NOPBT Margin	30.82%	32.08%	34.99%
Operating Taxes	221,000	83,000	(87,000)
Tax Rate	8.19%	3.18%
NOPAT	2,478,000	2,523,000	3,038,000
Net income	(592,000) 179.25%	(212,000) -77.37%	(937,000) 67.62%
Dividends
Dividend yield
Proceeds from repurchase of equity	(24,000)	644,000	(52,000)
BB yield	0.82%	-28.33%	0.52%
Debt
Debt current	450,000	432,000	49,932
Long-term debt	22,085,243	20,517,917	22,867,710
Deferred revenue
Other long-term liabilities	1,029,000	949,000	855,000
Net debt	21,588,243	20,385,917	22,335,643
Cash flow
Cash from operating activities	1,032,000	(728,000)	1,426,000
CAPEX	(215,000)	(268,000)	(283,000)
Cash from investing activities	(2,145,000)	(303,000)	409,000
Cash from financing activities	1,475,000	(474,000)	(1,513,000)
FCF	1,674,000	1,295,932	3,355,068
Balance
Cash	947,000	564,000	582,000
Long term investments
Excess cash	509,150	157,800	160,300
Stockholders' equity	(296,000)	101,000	(496,000)
Invested Capital	23,631,000	21,844,000	23,922,932
ROIC	10.90%	11.03%	12.29%
ROCE	11.49%	11.77%	12.32%
EV
Common stock shares outstanding	364,900	362,000	358,900
Price	8.02 27.71%	6.28 -77.25%	27.61 32.74%
Market cap	2,926,498 28.73%	2,273,360 -77.06%	9,909,229 34.20%
EV	25,454,741	23,611,277	32,316,872
EBITDA	3,963,000	4,000,000	4,503,000
EV/EBITDA	6.42	5.90	7.18
Interest	1,328,000	1,464,000	1,426,000
Interest/NOPBT	49.20%	56.18%	48.32%